Elligo’s Goes Direct approach uses electronic health records (EHRs) and other health data to identify physicians and patients for clinical studies.
“The partnership between Elligo and Allscripts allows CROs, Pharma, biotech and medical device companies access to the 97% of patients in healthcare settings that do not currently have access to clinical trials,” John Potthoff, PhD, Elligo CEO told Outsourcing-Pharma.com.
The Allscripts eParticipate service will be available to Allscripts clients using its EHR platforms. Physicians will have access to clinical trials across several therapeutic areas.
The initial relationship is set to last five years, Potthoff explained. “Elligo is currently conducting clinical trials under the Allscripts eParticipate model,” he added.
Allscripts senior vice president and general manager of Payer and Life Sciences, Jay Bhattacharyya, told us the company evaluated several approaches that would allow its providers’ to participate in clinical research, in an effort to continue its expansion into the clinical trials space.
The company identified Elligo's offering “as a highly valuable service that enabled that capability,” Bhattacharyya said, “and after engaging in a thorough assessment we determined that a collaboration of our solutions would best serve the Allscripts provider base that was interested in conducting research.”
Bhattacharyya explained, “the Allscripts provider network can benefit from [Elligo’s] services without any additional cost or resource investment, and has the ability to generate revenue from the Elligo offering.”
“Allscripts continues to provide innovative services that optimize clinical trials,” he added, “whether through efficiencies delivered to the research site to decrease trial costs, or to bring new clinical therapies to Allscripts patients while enabling revenue generating opportunities to the provider network.”